BeiGene Net Income/Loss 2014-2024 | ONC
BeiGene annual/quarterly net income/loss history and growth rate from 2014 to 2024. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- BeiGene net income/loss for the quarter ending September 30, 2024 was $-0.493B, a 4.13% decline year-over-year.
- BeiGene net income/loss for the twelve months ending September 30, 2024 was $-1.997B, a 44.46% decline year-over-year.
- BeiGene annual net income/loss for 2023 was $-0.882B, a 56% decline from 2022.
- BeiGene annual net income/loss for 2022 was $-2.004B, a 37.45% increase from 2021.
- BeiGene annual net income/loss for 2021 was $-1.458B, a 8.92% decline from 2020.
BeiGene Annual Net Income/Loss
(Millions of US $) |
| 2023 |
$-882 |
| 2022 |
$-2,004 |
| 2021 |
$-1,458 |
| 2020 |
$-1,601 |
| 2019 |
$-951 |
| 2018 |
$-674 |
| 2017 |
$-93 |
| 2016 |
$-119 |
| 2015 |
$-57 |
| 2014 |
$-19 |
| 2013 |
$-8 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
